The dramatic uptick in hospitalizations seen during the summer's delta surge was fueled by the highly transmissible variant spreading easily among mostly unvaccinated people, the CDC says. Read more:
from the Centers for Disease Control and Prevention suggests that although the delta variant is significantly more transmissible than prior variants, it is not more likely to lead to hospitalization.
The report, which analyzed COVID-19 hospitalization data from 14 states, also found that the proportion of people aged 18 to 49 hospitalized with delta increased"significantly" in July and August to 35.8% of all hospitalizations compared to 24.7% from January to June of this year. This was likely due to lower vaccination rates among younger people, the CDC said.Email this article
This efficacy estimate is from the company's clinical trial of 2,268 children in which some children got a placebo, and some children got the Pfizer vaccine. During the trial, 16 children who got the placebo shots developed COVID-19. Only three children who got the real vaccine developed COVID-19.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
Read more »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Read more »
Pfizer-BioNTech Covid-19 Booster Shot Was 95.6% Effective in Large Trial, Companies SayThe study was carried out while the highly contagious Delta variant was prevalent, the companies said, suggesting the booster helps protect against the contagious strain.
Read more »
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group. The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead. Details of Pfizer's study were posted online.
Read more »
Pfizer says COVID-19 vaccine more than 90% effective in kidsPfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing symptomatic infections in elementary school children
Read more »
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
Read more »